secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0001493152-24-025848
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma FY2024 revenue $56.6M (+65% YoY); operating profit $10.8M (+192%)
------------------------------------------------------------------------------

- Revenue of $56.6M, up $22.4M (65%) from prior fiscal year.
- Operating profit $10.8M, up $7.1M (192%) YoY.
- Net income attributable to common shareholders was $20.1M.
- Growth driven by commercial launch of Elite label product line in FY2024.
- Conference call on July 2, 2024 at 11:30 AM EDT for business update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224025848/0001493152-24-025848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224025848/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-025848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer